Overview

Safety Study of Hemospan® in Prostatectomy Patients

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is a progressive dose escalation study designed to evaluate the safety of Hemospan compared to a standard crystalloid solution (Ringer's lactate) in elective surgery patients undergoing total prostatectomy procedures with anticipated blood loss of more than 500 mL. Secondary objectives of this study are to observe possible activity of Hemospan for tissue oxygenation, perfusion and cardiovascular support.
Phase:
Phase 2
Details
Lead Sponsor:
Sangart
Treatments:
Pharmaceutical Solutions